Genmab — December 2017
-
Jeg forstår det således at antistoffet er modificeret, så det får lettere ved at danne denne hexamer, så CDC effekten bliver større - det virker som om complement systemet er ret avanceret, så flot hvis Genmab har fundet en vej til yderligere aktivering
-
-
Ja CDC-effekten forstærkes (og desuden også immuneffekten) af hexabody-klyngen. Men hvordan foregår kombinationen med et bispecifikt antistof? http://www.genmab.com/hexabody/Technology
-
Medwatch Morphosys alm info: http://medwatch.dk/secure/Medicinal___Biotek/article10073937.ece
-
-
Mit første gæt på duohexabodien kl 10.15 var vist temmelig forkert. Der må være tale om at de 6 antistoffer, som via hexabody teknologien har fået forbedret evnen til at danne klynger af 6 - simpelthen er bispecifikke. https://www.nature.com/scibx/journal/v7/n13/full/scibx.2014.363.html#f1
-
Nu er markedet negativt i dag pga Trumps skattesænkninger er udskudt. Så er det ikke så underligt at Genmab falder
https://www.cnbc.com/2017/11/30/senate-pushes-back-tax-bill-vote-as-setback-hits-in-final-hours.html -
....Building on our in-depth understanding of the mechanism of IgG4 Fab-arm exchange, we developed a powerful platform for the generation of stable bispecific IgG1 antibodies: the DuoBody platform. http://www.genmab.com/duobody/biology
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind